Amplifying the Power of Women in Chemistry

Merck & Co., Inc

Merck & Co., Inc., Wednesday, March 22, 2023, Press release picture

For Dr. Rebecca Ruck, having more women in science is personal. She remembers times early in her career when she was the only woman in the room. That's why she co-founded the Merck Research Award, given annually by the Women Chemists Committee (WCC) of the American Chemical Society, to recognize and mentor talented women scientists in their third and fourth year of graduate school with a research focus in one or more chemistry-related disciplines.

For Merck, it's a chance to build relationships with promising chemists and introduce them to the work the company does.

"A key to attracting talent - especially diverse talent - is to build relationships early in people's careers so they become familiar with our science, our people and our values," said Ruck, an associate vice president in process research and development for Merck.

For the awardees, it's a chance to present their research at the American Chemical Society (ACS) Fall National Meeting. They also receive a Merck mentor to prepare for their presentation at ACS and advise them on their career journey - an opportunity equally fulfilling for the mentors.

"That level of interaction with established chemists sets the program apart," said Anisha Patel, a director in analytical research and development, and lead of the program for Merck. "It's also a tremendous investment in diverse recruiting." Merck ultimately recruited three of the 2022 winners for future employment at the company.

Paying it forward for the next generation

When Ruck co-founded the award in 2015 along with Ann Weber, a former Merck chemist, she wanted to inspire the next generation of women in chemistry and build a community of scientists to support each other. Fast forward, and the WCC Merck Research Award fosters advancement for eight graduate students in chemistry annually. Last year, approximately 120 students applied.

One past honoree who's now a Merck colleague, Beryl Li, developed a long-term relationship with her mentor. "After I won, we would meet regularly," said Li, a senior scientist at the company's South San Francisco Discovery Center.

"My mentor was a significant factor in my decision to join Merck - and in my success at the company."

Beryl Li
Senior scientist

Those successes are also a reminder that every step forward matters. "There is still plenty of work needed to advance women - and all underrepresented groups - in science," Ruck said. "But thanks to initiatives like this one, we are making important progress."

Learn more about the WCC Merck Research Award.

Learn more about Merck's Environmental, Social & Governance (ESG) approach by visiting merck.com/company-overview/esg.

View original content here.

View additional multimedia and more ESG storytelling from Merck & Co., Inc. on 3blmedia.com.

Contact Info:
Spokesperson: Merck & Co., Inc.
Website: https://www.3blmedia.com/profiles/merck-co-inc
Email: info@3blmedia.com

SOURCE: Merck & Co., Inc.



View source version on accesswire.com:
https://www.accesswire.com/745302/Amplifying-the-Power-of-Women-in-Chemistry

News Provided by ACCESSWIRE via QuoteMedia

MRK
The Conversation (0)
Merck Announces First-Quarter 2023 Financial Results

Merck Announces First-Quarter 2023 Financial Results

First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines Total Worldwide Sales Were $14.5 Billion, a Decrease of 9% From First Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of... Keep Reading...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.... Keep Reading...
OTC:BCTXF

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health

Highlights: Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University. Merck to provide KEYTRUDA® for use in the combination study. The Investigator Grant... Keep Reading...

Merck Announces Q4 and Full-Year 2019 Financial Results

Merck (NYSE:MRK) reported quarterly worldwide sales at US$11.9 billion in Q4 in its financial results for the fourth quarter of 2019 and its full fiscal 2019 year. As quoted in the press release: As evidenced by our results and our 2020 guidance, Merck had an extraordinary year and is in a... Keep Reading...
OTC:BCTXF

BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.); Bria-IMT™ in combination with INCMGA00012 (by Incyte... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
Thian Chew, CEO of Invion

Invion Advances Global Strategy With New Licencing Agreement

Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market is set to surpass a total value of US$1.75 trillion by the end of the decade, according to Evaluate Pharma.Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma... Keep Reading...
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

4 Best-performing Canadian Pharma Stocks of 2025

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...

Latest Press Releases

Related News